Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in relapsed/refractory diffuse large B-cell lymphoma
2024-512115-50-00Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Karyopharm Therapeutics Inc. Started Jun 2016; status: completed.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-512115-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512115-50-00.